Mallinckrodt to settle U.S. drug marketing probe, fight kickback case

63

Mallinckrodt Plc on Wednesday said it had tentatively agreed to pay $15.4 million to resolve a U.S. Justice Department probe into how a drugmaker it now owns marketed an expensive treatment for a rare infant seizure disorder and multiple sclerosis.

http://feeds.reuters.com/~r/reuters/healthNews/~3/NekS_oWcVOA/mallinckrodt-to-settle-u-s-drug-marketing-probe-fight-kickback-case-idUSKCN1T6263